List of works - Annalisa Chiappella

A comprehensive review of lenalidomide therapy for B-cell non-Hodgkin lymphoma.

scientific article

A diachronic-comparative analysis for the identification of the most powerful prognostic index for localized diffuse large B-cell lymphoma.

scientific article

A phase II study on the role of gemcitabine plus romidepsin (GEMRO regimen) in the treatment of relapsed/refractory peripheral T-cell lymphoma patients

scientific article

Aggressive Non-Hodgkin lymphomas: risk factors and treatment of central nervous system recurrence

scientific article published on 08 August 2019

Analysis of the host pharmacogenetic background for prediction of outcome and toxicity in diffuse large B-cell lymphoma treated with R-CHOP21.

scientific article published on 29 January 2009

Antiviral treatment in patients with indolent B-cell lymphomas associated with HCV infection: a study of the Fondazione Italiana Linfomi.

scientific article published on 5 May 2014

Brentuximab vedotin in relapsed primary mediastinal large B-cell lymphoma: results from a phase 2 clinical trial

scientific article published on 06 March 2017

Brentuximab vedotin-based salvage treatment in Hodgkin's lymphoma

scientific article published on 16 August 2018

CD38, BCL-2, PD-1, and PD-1L expression in nodal peripheral T-cell lymphoma: Possible biomarkers for novel targeted therapies?

scientific article published on 3 October 2016

CNS relapse in patients with DLBCL treated with lenalidomide plus R-CHOP (R2CHOP): analysis from two phase 2 studies.

scientific article published on 26 June 2018

Central nervous system involvement in mantle cell lymphoma: clinical features, prognostic factors and outcomes from the European Mantle Cell Lymphoma Network

scientific article published on 24 April 2013

Clinical and molecular characterization of diffuse large B-cell lymphomas with 13q14.3 deletion.

scientific article published on 21 June 2011

Cyclophosphamide, doxorubicin, vincristine, prednisone and rituximab versus epirubicin, cyclophosphamide, vinblastine, prednisone and rituximab for the initial treatment of elderly "fit" patients with diffuse large B-cell lymphoma: results from the

scientific article published on 15 November 2011

Diffuse Large B-cell Lymphoma in the elderly: standard treatment and new perspectives

scientific article

Diffuse large B cell lymphoma cell of origin by digital expression profiling in the REAL07 Phase 1-2 study

scientific article published on 24 July 2017

Diffuse large B-cell lymphoma with concordant bone marrow involvement has peculiar genomic profile and poor clinical outcome.

scientific article

Dissection of DLBCL Microenvironment Provides a Gene Expression-Based Predictor of Survival Applicable to Formalin-Fixed Paraffin-Embedded Tissue

article

Dose-dense and high-dose chemotherapy plus rituximab with autologous stem cell transplantation for primary treatment of diffuse large B-cell lymphoma with a poor prognosis: a phase II multicenter study

scientific article published on 07 July 2009

Epigenomic evolution in diffuse large B-cell lymphomas

scientific article published on 20 April 2015

Gains of MYC locus and outcome in patients with diffuse large B-cell lymphoma treated with R-CHOP

Genomic alterations of ribosomal protein genes in diffuse large B cell lymphoma

article

Genomic lesions associated with a different clinical outcome in diffuse large B-Cell lymphoma treated with R-CHOP-21.

scientific article published on 31 August 2010

High-grade B-cell lymphoma: how to diagnose and treat

scientific article published on 19 June 2019

Highlights in lymphoma: overview of the 11th International Conference on Malignant Lymphoma.

scientific article published in October 2011

Histological transformation and secondary malignancies in follicular lymphoma

scientific article published on 01 November 2018

Impressive and durable response in a case of multiple relapsed mantle cell lymphoma treated with bortezomib and rituximab

scientific article published on 28 June 2016

Integrated profiling of diffuse large B-cell lymphoma with 7q gain

scientific article published on 21 March 2011

Integrating novel drugs to chemoimmunotherapy in diffuse large B-cell lymphoma.

scientific article published on 14 July 2017

Integration of transcriptional and mutational data simplifies the stratification of peripheral T-cell lymphoma

scientific article published on 19 March 2019

Intensified therapy in diffuse large B-cell lymphoma.

scientific article

Inter- and intratumoral heterogeneity of BCL2 correlates with IgH expression and prognosis in follicular lymphoma.

scientific article

Interim 18-FDG-PET/CT failed to predict the outcome in diffuse large B-cell lymphoma patients treated at the diagnosis with rituximab-CHOP.

scientific article published on 10 January 2012

Iron overload in patients receiving allogeneic hematopoietic stem cell transplantation: quantification of iron burden by a superconducting quantum interference device (SQUID) and therapeutic effectiveness of phlebotomy

scientific article

Khorana score and histotype predicts incidence of early venous thromboembolism in non-Hodgkin lymphomas

scientific article published on 27 April 2017

Lenalidomide in Pretreated Patients with Diffuse Large B-Cell Lymphoma: An Italian Observational Multicenter Retrospective Study in Daily Clinical Practice

scientific article published on 02 April 2019

Lenalidomide in diffuse large B-cell lymphomas.

scientific article published on 27 June 2012

Lenalidomide plus R-CHOP21 in elderly patients with untreated diffuse large B-cell lymphoma: results of the REAL07 open-label, multicentre, phase 2 trial

scientific article

Lenalidomide plus R-CHOP21 in newly diagnosed diffuse large B-cell lymphoma (DLBCL): long-term follow-up results from a combined analysis from two phase 2 trials

article

Lenalidomide plus cyclophosphamide, doxorubicin, vincristine, prednisone and rituximab is safe and effective in untreated, elderly patients with diffuse large B-cell lymphoma: a phase I study by the Fondazione Italiana Linfomi

scientific article

Monoclonal antibody-drug conjugates in B-cell lymphomas

scientific article published on 29 March 2019

Nonpegylated liposomal doxorubicin (MyocetTM) combination (R-COMP) chemotherapy in elderly patients with diffuse large B-cell lymphoma (DLBCL): results from the phase II EUR018 trial

scientific article published on 11 December 2009

Outcome prediction of diffuse large B-cell lymphomas associated with hepatitis C virus infection: a study on behalf of the Fondazione Italiana Linfomi

scientific article published on 22 November 2013

Persistence of minimal residual disease in bone marrow predicts outcome in follicular lymphomas treated with a rituximab-intensive program

scientific article published in October 2013

Positron Emission Tomography/Computed Tomography Assessment After Immunochemotherapy and Irradiation Using the Lugano Classification Criteria in the IELSG-26 Study of Primary Mediastinal B-Cell Lymphoma

scientific article published on 28 September 2016

Procalcitonin as a predictive marker of infections in chemoinduced neutropenia

scientific article published on 30 October 2009

Prognostic Role of Pre-Radiation Therapy (18)F-Fluorodeoxyglucose Positron Emission Tomography for Primary Mediastinal B-Cell Lymphomas Treated with R-CHOP or R-CHOP-Like Chemotherapy Plus Radiation

scientific article

ROBUST: Lenalidomide-R-CHOP versus placebo-R-CHOP in previously untreated ABC-type diffuse large B-cell lymphoma

scientific article published on 18 April 2016

Radiation therapy in primary mediastinal B-cell lymphoma with positron emission tomography positivity after rituximab chemotherapy

scientific article published on 2 August 2013

Rituximab and autologous stem-cell transplantation for high-risk diffuse large B-cell lymphoma - Authors' reply

scientific article published on 01 October 2017

Rituximab combined with MACOP-B or VACOP-B and radiation therapy in primary mediastinal large B-cell lymphoma: a retrospective study

scientific article published in October 2009

Rituximab maintenance compared with observation after brief first-line R-FND chemoimmunotherapy with rituximab consolidation in patients age older than 60 years with advanced follicular lymphoma: a phase III randomized study by the Fondazione Italia

scientific article published on 19 August 2013

Rituximab plus Bendamustine as front line treatment in frail elderly (>70 years) patients with diffuse large B-cell non-Hodgkin's lymphoma: a phase II multicenter study of the Fondazione Italiana Linfomi.

scientific article

Rituximab, bendamustine, and low-dose cytarabine as induction therapy in elderly patients with mantle cell lymphoma: a multicentre, phase 2 trial from Fondazione Italiana Linfomi

scientific article

Rituximab-dose-dense chemotherapy with or without high-dose chemotherapy plus autologous stem-cell transplantation in high-risk diffuse large B-cell lymphoma (DLCL04): final results of a multicentre, open-label, randomised, controlled, phase 3 study

scientific article published on 28 June 2017

Role of whole-body [18F] fluorodeoxyglucose positron emission tomography/computed tomography (FDG-PET/CT) and conventional techniques in the staging of patients with Hodgkin and aggressive non Hodgkin lymphoma.

scientific article published on 14 April 2008

Safety and efficacy of rituximab plus bendamustine in relapsed or refractory diffuse large B-cell lymphoma patients: an Italian retrospective multicenter study.

scientific article published on 15 December 2015

Salvage regimens for Hodgkin's lymphoma in the brentuximab vedotin era.

scientific article published on 21 December 2017

Single-agent panobinostat for relapsed/refractory diffuse large B-cell lymphoma: clinical outcome and correlation with genomic data. A phase 2 study of the Fondazione Italiana Linfomi

scientific article published on 04 April 2018

State-of-the-art Therapy for Advanced-stage Diffuse Large B-cell Lymphoma.

scientific article published on December 2016

The risk of CNS involvement in aggressive lymphomas in the rituximab era.

scientific article published on 30 October 2013

Time to progression of mantle cell lymphoma after high-dose cytarabine-based regimens defines patients risk for death

scientific article published on 08 November 2018

Update in indolent non-Hodgkin lymphoma (NHL): paradigm for Waldenström's macroglobulinemia (WM)

scientific article published on 01 February 2011

Update on the molecular pathogenesis and clinical treatment of mantle cell lymphoma: report of the 11th annual conference of the European Mantle Cell Lymphoma Network

scientific article

XVI. CNS prophylaxis in aggressive lymphomas: for whom and how.

scientific article published on June 2013

Yttrium-90 ibritumomab tiuxetan (Zevalin) followed by BEAM (Z-BEAM) conditioning regimen and autologous stem cell transplantation (ASCT) in relapsed or refractory high-risk B-cell non-Hodgkin lymphoma (NHL): a single institution Italian experience.

scientific article published on 16 April 2018

List of works by Annalisa Chiappella

A comprehensive review of lenalidomide therapy for B-cell non-Hodgkin lymphoma.

A diachronic-comparative analysis for the identification of the most powerful prognostic index for localized diffuse large B-cell lymphoma.

A phase II study on the role of gemcitabine plus romidepsin (GEMRO regimen) in the treatment of relapsed/refractory peripheral T-cell lymphoma patients

Aggressive Non-Hodgkin lymphomas: risk factors and treatment of central nervous system recurrence

Analysis of the host pharmacogenetic background for prediction of outcome and toxicity in diffuse large B-cell lymphoma treated with R-CHOP21.

Antiviral treatment in patients with indolent B-cell lymphomas associated with HCV infection: a study of the Fondazione Italiana Linfomi.

Brentuximab vedotin in relapsed primary mediastinal large B-cell lymphoma: results from a phase 2 clinical trial

Brentuximab vedotin-based salvage treatment in Hodgkin's lymphoma

CD38, BCL-2, PD-1, and PD-1L expression in nodal peripheral T-cell lymphoma: Possible biomarkers for novel targeted therapies?

CNS relapse in patients with DLBCL treated with lenalidomide plus R-CHOP (R2CHOP): analysis from two phase 2 studies.

Central nervous system involvement in mantle cell lymphoma: clinical features, prognostic factors and outcomes from the European Mantle Cell Lymphoma Network

Clinical and molecular characterization of diffuse large B-cell lymphomas with 13q14.3 deletion.

Cyclophosphamide, doxorubicin, vincristine, prednisone and rituximab versus epirubicin, cyclophosphamide, vinblastine, prednisone and rituximab for the initial treatment of elderly "fit" patients with diffuse large B-cell lymphoma: results from the

Diffuse Large B-cell Lymphoma in the elderly: standard treatment and new perspectives

Diffuse large B cell lymphoma cell of origin by digital expression profiling in the REAL07 Phase 1-2 study

Diffuse large B-cell lymphoma with concordant bone marrow involvement has peculiar genomic profile and poor clinical outcome.

Dissection of DLBCL Microenvironment Provides a Gene Expression-Based Predictor of Survival Applicable to Formalin-Fixed Paraffin-Embedded Tissue

Dose-dense and high-dose chemotherapy plus rituximab with autologous stem cell transplantation for primary treatment of diffuse large B-cell lymphoma with a poor prognosis: a phase II multicenter study

Epigenomic evolution in diffuse large B-cell lymphomas

Gains of MYC locus and outcome in patients with diffuse large B-cell lymphoma treated with R-CHOP

Genomic alterations of ribosomal protein genes in diffuse large B cell lymphoma

Genomic lesions associated with a different clinical outcome in diffuse large B-Cell lymphoma treated with R-CHOP-21.

High-grade B-cell lymphoma: how to diagnose and treat

Highlights in lymphoma: overview of the 11th International Conference on Malignant Lymphoma.

Histological transformation and secondary malignancies in follicular lymphoma

Impressive and durable response in a case of multiple relapsed mantle cell lymphoma treated with bortezomib and rituximab

Integrated profiling of diffuse large B-cell lymphoma with 7q gain

Integrating novel drugs to chemoimmunotherapy in diffuse large B-cell lymphoma.

Integration of transcriptional and mutational data simplifies the stratification of peripheral T-cell lymphoma

Intensified therapy in diffuse large B-cell lymphoma.

Inter- and intratumoral heterogeneity of BCL2 correlates with IgH expression and prognosis in follicular lymphoma.

Interim 18-FDG-PET/CT failed to predict the outcome in diffuse large B-cell lymphoma patients treated at the diagnosis with rituximab-CHOP.

Iron overload in patients receiving allogeneic hematopoietic stem cell transplantation: quantification of iron burden by a superconducting quantum interference device (SQUID) and therapeutic effectiveness of phlebotomy

Khorana score and histotype predicts incidence of early venous thromboembolism in non-Hodgkin lymphomas

Lenalidomide in Pretreated Patients with Diffuse Large B-Cell Lymphoma: An Italian Observational Multicenter Retrospective Study in Daily Clinical Practice

Lenalidomide in diffuse large B-cell lymphomas.

Lenalidomide plus R-CHOP21 in elderly patients with untreated diffuse large B-cell lymphoma: results of the REAL07 open-label, multicentre, phase 2 trial

Lenalidomide plus R-CHOP21 in newly diagnosed diffuse large B-cell lymphoma (DLBCL): long-term follow-up results from a combined analysis from two phase 2 trials

Lenalidomide plus cyclophosphamide, doxorubicin, vincristine, prednisone and rituximab is safe and effective in untreated, elderly patients with diffuse large B-cell lymphoma: a phase I study by the Fondazione Italiana Linfomi

Monoclonal antibody-drug conjugates in B-cell lymphomas

Nonpegylated liposomal doxorubicin (MyocetTM) combination (R-COMP) chemotherapy in elderly patients with diffuse large B-cell lymphoma (DLBCL): results from the phase II EUR018 trial

Outcome prediction of diffuse large B-cell lymphomas associated with hepatitis C virus infection: a study on behalf of the Fondazione Italiana Linfomi

Persistence of minimal residual disease in bone marrow predicts outcome in follicular lymphomas treated with a rituximab-intensive program

Positron Emission Tomography/Computed Tomography Assessment After Immunochemotherapy and Irradiation Using the Lugano Classification Criteria in the IELSG-26 Study of Primary Mediastinal B-Cell Lymphoma

Procalcitonin as a predictive marker of infections in chemoinduced neutropenia

Prognostic Role of Pre-Radiation Therapy (18)F-Fluorodeoxyglucose Positron Emission Tomography for Primary Mediastinal B-Cell Lymphomas Treated with R-CHOP or R-CHOP-Like Chemotherapy Plus Radiation

ROBUST: Lenalidomide-R-CHOP versus placebo-R-CHOP in previously untreated ABC-type diffuse large B-cell lymphoma

Radiation therapy in primary mediastinal B-cell lymphoma with positron emission tomography positivity after rituximab chemotherapy

Rituximab and autologous stem-cell transplantation for high-risk diffuse large B-cell lymphoma - Authors' reply

Rituximab combined with MACOP-B or VACOP-B and radiation therapy in primary mediastinal large B-cell lymphoma: a retrospective study

Rituximab maintenance compared with observation after brief first-line R-FND chemoimmunotherapy with rituximab consolidation in patients age older than 60 years with advanced follicular lymphoma: a phase III randomized study by the Fondazione Italia

Rituximab plus Bendamustine as front line treatment in frail elderly (>70 years) patients with diffuse large B-cell non-Hodgkin's lymphoma: a phase II multicenter study of the Fondazione Italiana Linfomi.

Rituximab, bendamustine, and low-dose cytarabine as induction therapy in elderly patients with mantle cell lymphoma: a multicentre, phase 2 trial from Fondazione Italiana Linfomi

Rituximab-dose-dense chemotherapy with or without high-dose chemotherapy plus autologous stem-cell transplantation in high-risk diffuse large B-cell lymphoma (DLCL04): final results of a multicentre, open-label, randomised, controlled, phase 3 study

Role of whole-body [18F] fluorodeoxyglucose positron emission tomography/computed tomography (FDG-PET/CT) and conventional techniques in the staging of patients with Hodgkin and aggressive non Hodgkin lymphoma.

Safety and efficacy of rituximab plus bendamustine in relapsed or refractory diffuse large B-cell lymphoma patients: an Italian retrospective multicenter study.

Salvage regimens for Hodgkin's lymphoma in the brentuximab vedotin era.

Single-agent panobinostat for relapsed/refractory diffuse large B-cell lymphoma: clinical outcome and correlation with genomic data. A phase 2 study of the Fondazione Italiana Linfomi

State-of-the-art Therapy for Advanced-stage Diffuse Large B-cell Lymphoma.

The risk of CNS involvement in aggressive lymphomas in the rituximab era.

Time to progression of mantle cell lymphoma after high-dose cytarabine-based regimens defines patients risk for death

Update in indolent non-Hodgkin lymphoma (NHL): paradigm for Waldenström's macroglobulinemia (WM)

Update on the molecular pathogenesis and clinical treatment of mantle cell lymphoma: report of the 11th annual conference of the European Mantle Cell Lymphoma Network

XVI. CNS prophylaxis in aggressive lymphomas: for whom and how.

Yttrium-90 ibritumomab tiuxetan (Zevalin) followed by BEAM (Z-BEAM) conditioning regimen and autologous stem cell transplantation (ASCT) in relapsed or refractory high-risk B-cell non-Hodgkin lymphoma (NHL): a single institution Italian experience.